Abbott
(NYSE: ABT)
is launching the latest generation of its Navitor heart valve technology in the U.S., according to one company official.
In a post on LinkedIn, Chris Waddell, Abbott’s U.S. VP for transcatheter aortic valve implantation (TAVI), shared the news of the launch. The latest version — called the Navitor Vision — features a range of enhancements compared to the previous version.
“I’m excited to share Abbott is launching the latest generation of Navitor in the U.S.-Navitor Vision,” Waddell wrote in the post. “Abbott is going big in TAVI!”
Waddell shared that the features include stable and precise delivery, excellent hemodynamics and low paravalvular leak (PVL) rates. Abbott built the system upon a proven, durable platform with a future-ready design, the VP added.
Additionally, Navitor Vision features highly visible markers. These markers help identify 3MM-4.5MM depth, optimizing implant confidence and patient outcomes.
In a video posted by Waddle, Abbott called the system “bigger,” brighter” and “better.” The company labeled it as its “largest valve” with the “smallest delivery system.”
Abbott originally entered the U.S. TAVR and TAVI market in 2021 with FDA approval of its Portico with FlexNav system. The company now competes in a space dominated by Edwards Lifesciences and Medtronic to date.
In January 2023, the company won FDA approval for the Navitor system. It designed Navitor as the only self-expanding TAVI system with leaflets within the native valve. This design helps improve access to coronary arteries to facilitate future procedures that treat coronary artery disease.